Publications

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

Download PDF
Resource: ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

.

Related Articles

Proliferative CD8 T-cells : A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma

Link
Ultra-fast and automated immunohistofluorescent multistaining using a microfluidic tissue processor

Link